Publications

Impact of Prior Therapy on Efficacy and Safety of Oral Ixazomib-Lenalidomide-Dexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) in Tourmaline-Mm1.

AuthID
P-00R-HSM

Author(s)

Mateos, MV

Masszi, T

Grzasko, N

Hansson, M

Sandhu, I

Pour, L

Viterbo, L

Jackson, SR

Stoppa, AM

Gimsing, P

Hamadani, M

Borsaru, G

Berg, D

Lin, JC

Van De Velde, H

Richardson, PG

Moreau, P

Document Type

Abstract

Year published

2016

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 34, Issue: 15

Conference

Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: JUN 03-07, 2016, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1200/jco.2016.34.15_suppl.8039

Wos: WOS:000404711505194

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Impact of Prior Therapy on Efficacy and Safety of Oral Ixazomib-Lenalidomide-Dexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) in Tourmaline-Mm1.

Useful Links

Get Help

Federated Authentication (Click on the image)

Impact of Prior Therapy on Efficacy and Safety of Oral Ixazomib-Lenalidomide-Dexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) in Tourmaline-Mm1.

Useful Links

Get Help